All In Biotech

Drug Trial Radar · NCT05852873

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

May 12, 2023

Primary completion

Sep 9, 2025

Study completion Jun 11, 2027

Sponsor

Lead sponsor
Haukeland University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Bergen; Oslo University Hospital; University of Oslo; St. Olavs Hospital; Norwegian University of Science and Technology
First posted
May 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old. The main question it aims to answer is: Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo. Participants with acute COVID-19, documented with positive lateral flow test or PCR, within the last 5 days will be randomised to take either Paxlovid or placebo. All participants will receive standard of care in addition. Participants will respond to electronic questionnaires at 14 time points during follow-up. The primary outcome is presence of long-COVID symptoms at 3 months follow-up. Researchers will compare participants who received Paxlovid and placebo to see if Paxlovid treatment can prevent the occurrence of long-COVID.

Conditions

  • Post COVID-19 Condition, Unspecified
  • SARS-CoV2 Infection
  • COVID-19

Interventions

  • Nirmatrelvir/ritonavirDrug

    Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.

  • PlaceboDrug

    Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptoms of long-COVIDTime frame: Change in symptoms from baseline to 3, 6 and 12 months follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Haukeland University Hospital

    Bergen, Vestland, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.